Mumbai, July 31 -- Revenue from sales climbed 10.14% YoY to Rs 15,183.55 crore in Q1 FY27.

Profit before exceptional items and tax rose 7.82% to Rs 4,302.90 crore from Rs 3,990.77 crore a year earlier. The company reported exceptional items of Rs 204.09 crore during the quarter, including a charge of Rs 167 crore towards due diligence, legal, filing and other transaction-related expenses incurred for the proposed acquisition of Organon & Co. Sun Pharma said additional acquisition-related costs are expected in the coming quarters.

EBITDA increased 2.7% year-on-year to Rs 4,417.7 crore in Q1 FY27. However, the EBITDA margin contracted to 28.9% in Q1 FY27 from 31.1% in the year-ago period.

India continued to be the company's strongest mar...